We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Unspecified Safety Signal Halts Takeda’s Narcolepsy Studies
Unspecified Safety Signal Halts Takeda’s Narcolepsy Studies
An unspecified safety signal has slammed the brakes on Takeda Pharmaceutical’s twin studies of TAK-994, an investigational oral orexin agonist intended for the treatment of excessive daytime sleepiness in patients with narcolepsy type 1 (NT1), a chronic neurological disorder that alters the sleep-wake cycle.